Cytokinetics Company Profile
What is the competitive landscape for CYTOKINETICS
CYTOKINETICS has one approved drug.
There are two US patents protecting CYTOKINETICS drugs.
Drugs and US Patents for Cytokinetics
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-003 | Dec 19, 2025 | RX | Yes | No | 10,836,755 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-001 | Dec 19, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-004 | Dec 19, 2025 | RX | Yes | No | 10,836,755 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-003 | Dec 19, 2025 | RX | Yes | No | 12,370,179 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-001 | Dec 19, 2025 | RX | Yes | Yes | 10,836,755 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-002 | Dec 19, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cytokinetics Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2026113610 | ⤷ Start Trial |
| Lithuania | PA2026525 | ⤷ Start Trial |
| Morocco | 51620 | ⤷ Start Trial |
| Portugal | 3740481 | ⤷ Start Trial |
| Hungary | E070699 | ⤷ Start Trial |
| Taiwan | 202320763 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cytokinetics Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3740481 | CA 2026 00034 | Denmark | ⤷ Start Trial | PRODUCT NAME: AFICAMTEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/25/2014 20260213 |
| 3740481 | 202640026 | Slovenia | ⤷ Start Trial | PRODUCT NAME: AFICAMTEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/25/2014; DATE OF NATIONAL AUTHORISATION: 20260212; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 3740481 | 301392 | Netherlands | ⤷ Start Trial | PRODUCT NAME: AFICAMTEN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/25/2014 20260213 |
| 3740481 | 2026C/731 | Belgium | ⤷ Start Trial | PRODUCT NAME: AFICAMTEN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/25/2014 20260213 |
| 3740481 | LUC50059 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: AFICAMTEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/25/2014 20260213 |
| 3740481 | PA2026525 | Lithuania | ⤷ Start Trial | PRODUCT NAME: AFIKAMTENAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/25/2014 20260212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

